Covid-19 Rapid Antigen Test

CareStart is intended for use by medical professionals

  • Lateral Flow Test
  • Results at 10 minutes
  • Anterior Nares: 87.2% sensitivity, 100% specificity
    Nasopharyngeal: 93.8 % sensitivity, 99.3% specificity
  • No special equipment required
  • Now available worldwide
Thank You!  
One of our dedicated team members will contact you promptly.
Oops! Something went wrong while submitting the form.
This form is intended for sale and distribution of CareStart tests to distributors, clinics, and medical professionals. CareStart is not a clinic or facility and does not provide on site testing services. For at home tests, please visit letsongo.com

The CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within the first five days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high, or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

NOTE: For Serial Screening of asymptomatic individuals. The serial screening indication is only applied to products manufactured by Access Bio Inc. after April 12, 2021.

As of December 2nd, 2021, the FDA has granted an additional shelf-life extension for CareStart , from twelve months to sixteen (16) months. Please view the Official Notification Letter for more information on expiration dates.

  • Lateral flow assay
  • Detect SARS-CoV-2 nucleocapsid protein antigen
  • Rapid results within 10-15 minutes
  • Intended at POC setting (i.e., in patient care settings) by medical professionals operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
  • For use under the Emergency Use Authorization (EUA) only
  • For in vitro diagnostic use only
  • For prescription use only
  • For use with direct anterior nasal and nasopharyngeal swab specimens

KIT COMPONENTS

  • 20 Test devices
  • 20 Assay buffer
  • 20 Extraction vials and caps
  • 20 Specimen collection swabs
  • 1 Positive and 1 negative control swabs
  • 1 Instructions for Use

The CareStart™ COVID-19 Antigen test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories and at the Point of Care by medical professionals operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only to detect the presence of the SARS-CoV-2 nucleocapsid protein antigen, not for any other viruses or pathogens; this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

CareStart How to Video

Meet our preferred distributors